0351 Trends in Insomnia Diagnosis Among Medicare Beneficiaries, 2006–2013. (27th April 2018)

• Record Type: Journal Article
• Authors: Albrecht, J S; Tom, S E; Vadlamani, A; Scharf, S M; Wickwire, E M
• Is Part Of: Sleep. Volume 41(2018)Supplement 1
• Page Start: A135
• Page End: A135
• Publication Date: 2018-04-27
• Subjects: Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsy061.350
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: Introduction: Sleep complaints increase across the lifespan, with half of older adults reporting poor sleep quality. The most common diagnosis is insomnia disorder, which is associated with increased morbidity and health care utilization among older adults. Despite its high prevalence and substantial adverse consequences, few population-level studies have examined longitudinal trends in insomnia diagnoses in the US. The objective of this study was to characterize trends in insomnia diagnoses among Medicare fee-for-service beneficiaries over a seven-year period. Methods: We conducted a time-series analysis to estimate the annual prevalence of insomnia using a randomly selected 5% sample of Medicare fee-for-service beneficiaries from 2006–2013. Insomnia was defined as the presence at least one inpatient or outpatient claim containing pertinent International Classification of Disease - Ninth Edition - Clinical Modification codes (307.41, 307.42, 307.49, 327.00, 327.01, 327.09, 780.52, V69.4). We also identified annual receipt of any insomnia-related medications from Part D prescription drug claims (barbiturates, benzodiazepines, chloral hydrate, hydroxyzine, non-benzodiazepine sedative hypnotics [NBSH], and sedating anti-depressants). Results: Prevalence of insomnia diagnoses increased from 4.2% in 2006 to 6.1% in 2013 (p<0.001). The prevalence of either insomnia diagnosis or insomnia medication use remained close to 24% from 2006 to 2012 and subsequently increased to in 28% 2013 (p=0.04). Women were slightly more likely to have an insomnia diagnosis than men in all years (p<0.001), with prevalence of 5–6% in women and 4–5% in men. In 2013, prevalence of either insomnia diagnosis or insomnia medication use was 24% in men and 31% in women. Conclusion: Insomnia diagnoses increased from 2006 to 2013 among Medicare fee-for-service beneficiaries. This suggests a need to focus on recognition and treatment of insomnia and related conditions among this population. Support (If Any): Merck Investigator-Initiated Studies Program (PI: Wickwire).